麻豆约拍

Remdesivir, a Coronavirus treatment, gets approval for limited use in the US - Wall Street Journal reporter Joseph Walker tells us more about the firm behind it, Gilead, and the US public's attitude to paying for the new drug. The aviation industry continues to receive bad news today - Bjorn Fehrm is an aviation analyst and tells us which airlines are expecting deep cuts for years to come. Plus, why are the stock markets doing surprisingly well, whilst global economy and businesses reel from lockdowns due to Covid-19? US radio station Marketplace's Kai Ryssdal speaks to Anat Admati, a finance professor at Stanford, to unravel the conflicted messages. Plus, how is university funding managing to keep its students in education? Finally, we delve in to the day's stock market movements with Chris Low of FTN Financial in the US.

(Image: One vial of the drug Remdesivir seen in Germany. Photo by ULRICH PERREY/POOL/AFP via Getty Images)